Research programme: cancer fatigue therapeutics - Dimerix Bioscience
Latest Information Update: 05 Aug 2016
At a glance
- Originator Dimerix Bioscience
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Fatigue
Highest Development Phases
- Research Fatigue
Most Recent Events
- 05 Aug 2016 Early research in Fatigue in Australia (unspecified route)
- 05 Aug 2016 Research programme: cancer fatigue therapeutics - Dimerix Bioscience is available for licensing as of 05 Aug 2016. http://dimerix.com/